Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter purchased 130,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $4.01 per share, for a total transaction of $521,300.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vital Therapies, Inc. (NASDAQ VTL) traded up 3.70% on Thursday, hitting $4.20. 535,405 shares of the stock traded hands. The stock’s market cap is $177.27 million. The stock has a 50-day moving average price of $3.01 and a 200 day moving average price of $3.36. Vital Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $6.58.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01. During the same quarter in the prior year, the company earned ($0.30) EPS. On average, equities analysts expect that Vital Therapies, Inc. will post ($1.31) EPS for the current fiscal year.

WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/vital-therapies-inc-vtl-director-muneer-a-satter-purchases-130000-shares.html.

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Vital Therapies by 102.9% during the 1st quarter. FMR LLC now owns 2,957,878 shares of the company’s stock valued at $11,832,000 after purchasing an additional 1,500,000 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Vital Therapies by 1.2% during the 2nd quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after purchasing an additional 29,840 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after purchasing an additional 168,705 shares during the last quarter. UBS Oconnor LLC bought a new position in Vital Therapies during the 1st quarter valued at about $800,000. Finally, LMR Partners LLP bought a new position in Vital Therapies during the 2nd quarter valued at about $396,000. 25.58% of the stock is owned by hedge funds and other institutional investors.

VTL has been the topic of several analyst reports. ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Raymond James Financial, Inc. initiated coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They issued an “outperform” rating and a $6.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $8.00.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.